Continued access to the Endogenex device study for type 2 diabetes
Part of Hormones & metabolism clinical trials.
This trial offers continued access to the Endogenex system for people who were in the sham (placebo) group of the ReCET study and have completed their 12-month visit. It tests a device that treats the duodenum to improve blood sugar control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were in the sham (placebo) group of the ReCET study and finished your 12-month checkup.
- Your average blood sugar (HbA1c) is between 7.0 and 10.5%.
- Your body mass index (BMI) is less than 40.
- You have type 2 diabetes, not type 1 diabetes.
- You have not used insulin for more than 1 month in the last 2 years.
- You are willing to avoid donating blood while in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called SHR-3167 in people with type 2 diabetes. The goal is to see how the drug works in the body and how it affects blood sugar. It may be an option for adults who have had diabetes for at least 6 months.
This registry collects information from people with type 2 diabetes who have already been treated with the Endogenex System. It helps researchers learn how the treatment works over time.
This is a screening study to identify and understand people with type 2 diabetes whose blood sugar isn't well controlled, so they can potentially join future diabetes research trials. You won't receive a new treatment in this study—it's about getting to know your health history and seeing if you might be a good fit for upcoming studies.
This study tests a procedure called pulsENDO therapy, which uses a device placed in the upper part of the gut during a scope procedure to try to improve blood sugar control in adults with type 2 diabetes. It aims to see if this treatment can help lower HbA1c levels, which indicate blood sugar control, and possibly reduce the need for diabetes medications.
This trial tests a new medicine, LY4057996, in people with type 1 or type 2 diabetes and in healthy volunteers. It aims to see if the drug is safe and how it works in the body.
This study tests the ROME GS System, a glucose monitoring device that measures blood sugar levels. The system includes a sensor placed under the skin and a transmitter worn on the body. If you have diabetes and want to help evaluate a new way to track your blood sugar, this trial may be for you.
Hear when a new Type2diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.